Swipe om te navigeren naar een ander artikel
This study compared the subjective quality of life (SQOL) in schizophrenia patients living with their families in Hong Kong (HK) and Beijing (BJ) and explored the relationship between SQOL and basic socio-demographic and clinical factors.
Two hundred and sixty-four clinically stable outpatients with schizophrenia were randomly selected in HK and 258 counterparts matched according to age, sex, age at onset, and length of illness in BJ. SQOL and psychiatric status were assessed with standard rating instruments.
There was no significant difference in any of SQOL domains between the two cohorts after controlling for potentially confounding variables. Positive, depressive and anxiety symptoms and drug-induced extrapyramidal side effects (EPS) were all significantly correlated with SQOL. Multiple regression analysis revealed that only depressive symptoms predicted all SQOL domains in both groups. Having removed depressive symptoms from the model, positive symptoms predicted all domains, anxiety predicted all but social domains, use of benzodiazepines (BZD) predicted all but physical domains, EPS predicted physical domain, and history of suicide predicted social domain in HK; anxiety predicted all domains, positive symptoms predicted all but physical domains, EPS, use of BZD and history of suicide all predicted physical domains, and length of illness predicted environmental domain in BJ.
Despite considerable differences between the two sites in terms of health care delivery and the economic conditions of the subjects, SQOL did not differ between HK and BJ. The conclusion is in line with previous studies that suggested that patients’ SQOL was independent of their living standard as long as it reached a certain minimum level. SQOL was more strongly related to the severity of depressive symptoms and had weak association with socio-demographic factors.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Chen, C. H., Shen, Y. C., Zhang, W. X., Li, S. R., Huang, Y. Q., Wang, J. R., & Wang, D. P. (1998). Epidemiological survey on schizophrenia in seven areas of China (in Chinese). The Chinese Journal of Psychiatry, 31, 72–74.
Weng, Y. Z., Xu, M. J., Li, D. L, Guo, F. Y., Huang, Q., & Fu, T. (2001). Assessment of expressed emotion in family members of schizophrenic patients in Beijing. Modern Rehabilitation, 5, 39–42.
Phillips, M. R., & Pearson, V. (1994). Future opportunities and challenges for the development of psychiatric rehabilitation in China. The British Journal of Psychiatry, 165(Suppl), 128–142.
Sartorius, N. (1997). Quality of life and mental disorders: A global perspective. Chichester: John Wiley.
Warner, R., de Girolamo, G., Belelli, G., Bologna, C., Fioritti, A., & Rosini, G. (1998). The quality of life of people with schizophrenia in Boulder, Colorado, and Bologna, Italy. Schizophrenia Bulletin, 24, 559–568. PubMed
Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). New York: Erlbaum Hillsdale.
Fang, J. Q., Hao, Y. T., & Li, C. X. (1999). Reliability and validity for Chinese version of WHO quality of life scale (in Chinese). Chinese Mental Health Journal, 13, 203–205.
WHO (1995). The World Health Organization Quality of Life assessment (WHOQOL): Position paper from the World Health Organization. Social Science & Medicine, 41, 1403–1409. CrossRef
Overall, J. E., & Beller, S. A. (1984). The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research: I. Factor structure on an inpatient unit. Journal of Gerontology, 39, 187–193. PubMed
Barnes, T. R. (1989). A rating scale for drug-induced akathisia. The British Journal of Psychiatry, 154, 672–676. PubMed
Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry, 23, 56–62. PubMed
Wegener, S., Redoblado-Hodge, M. A., Lucas, S., Fitzgerald, D., Harris, A., & Brennan, J. (2005). Relative contributions of psychiatric symptoms and neuropsychological functioning to quality of life in first-episode psychosis. The Australian and New Zealand Journal of Psychiatry, 39, 487–492. PubMedCrossRef
Hansson, L., Middelboe, T., Sorgaard, K. W., Bengtsson-Tops, A., Bjarnason, O., Merinderv, L., Nilsson, L., Sandlund, M., Korkeila, J., & Vinding, H. R. (2002). Living situation, subjective quality of life and social network among individuals with schizophrenia living in community settings. Acta Psychiatrica Scandinavica, 106, 343–350. PubMedCrossRef
Patterson, T. L., Shaw, W., Semple, S. J., Moscona, S., Harris, M. J., Kaplan, R. M., Grant, I., & Jeste, D. V. (1997). Health-related quality of life in older patients with schizophrenia and other psychoses: Relationships among psychosocial and psychiatric factors. International Journal of Geriatric Psychiatry, 12, 452–461. PubMedCrossRef
Eronen, M. (1995). Mental disorders and homicidal behavior in female subjects. The American Journal of Psychiatry, 152, 1216–1218. PubMed
Yuen, C. H. (2004). Guideline on PFU system. In Doctors’ handbook. Hong Kong: Castle Peak Hospital.
Luo, K., & Yu, D. (1994). Enterprise-based sheltered workshops in Nanjing. A new model for the community rehabilitation of mentally ill workers. The British Journal of Psychiatry Supplement, 165, 89–95.
Phillips, M. R., Lu, S. H., & Wang, R. W. (1997). Economic reforms and the acute inpatient care of patients with schizophrenia: The Chinese experience. The American Journal of Psychiatry, 154, 1228–1234. PubMed
Ng, C. (2007). Role of international collaboration in facilitating mental halth system change. In WPA Regional Conference/CSP Annual Congress. Shanghai, China, September 20–23, pp. 162–163.
Sim, K., Su, A., Fujii, S., Yang, S. Y., Chong, M. Y., Ungvari, G. S., Si, T., Chung, E. K., Tsang, H. Y., Chan, Y. H., Heckers, S., Shinfuku, N., & Tan, C. H. (2004). Antipsychotic polypharmacy in patients with schizophrenia: A multicentre comparative study in East Asia. British Journal of Clinical Pharmacology, 58, 178–183. PubMedCrossRef
Lehman, A. F. (1988). A quality of life interview for the chronically mentally ill. Evaluation and Program Planning, 11, 51–62. CrossRef
Awad, A. G. (1992). Quality of life of schizophrenic patients on medications and implications for new drug trials. Hospital & Community Psychiatry, 43, 262–265.
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S., Davis, S. M., Davis, C. E., Lebowitz, B. D., Severe, J., & Hsiao, J. K. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine, 353, 1209–1223. PubMedCrossRef
Jones, P. B., Barnes, T. R., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006). Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry, 63, 1079–1087. PubMedCrossRef
- Subjective quality of life in outpatients with schizophrenia in Hong Kong and Beijing: relationship to socio-demographic and clinical factors
Gabor S. Ungvari
- Springer Netherlands